Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1

Conditions

Sarcoma 1571Glioblastoma 512Gliosarcoma 485Osteosarcoma 458Brain Neoplasms 344Gastrointestinal Stromal Tumors 326Central Nervous System Neoplasms 296Neoplasms 291Dendritic Cell Sarcoma, Interdigitating 286Astrocytoma 275Lymphoma 259Bone Neoplasms 245Breast Neoplasms 238Sarcoma, Ewing 237Glioma 236Neuroblastoma 230Rhabdomyosarcoma 226Melanoma 224Precursor Cell Lymphoblastic Leukemia-Lymphoma 218Recurrence 216Lymphoma, Non-Hodgkin 216Burkitt Lymphoma 213Oligodendroglioma 203Ovarian Neoplasms 202Lymphoma, Large B-Cell, Diffuse 187Neoplasm Metastasis 186Lymphoma, Follicular 172Leukemia 164Leukemia, Lymphocytic, Chronic, B-Cell 158Hodgkin Disease 158

Interventions

pevonedistat 1Vincristine 1Rituximab 1Prednisone 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Acromesomelic dysplasia, Maroteaux type × Sarcoma × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡